Anaerobic membrane biological treatment device and method for degradation-resistant pharmaceutical wastewater

By building a denitrification enhancement system in an anaerobic digestion system, using nitronitrogen to promote the hydrolysis and ring opening of aniline, combined with anaerobic membrane bioreaction technology, the problem of difficulty in removing organic matter from pharmaceutical wastewater in the existing technology is solved, and the problem of difficult degradation of organic matter in pharmaceutical wastewater is achieved. Efficient pollutant degradation and energy recovery, improving treatment effect and water quality.

CN119038743APending Publication Date: 2024-11-29SUZHOU UNIV OF SCI & TECH

Patent Information

Application Number
CN202411246461.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing biological treatment methods are difficult to effectively remove difficult-to-degrade organic matter such as aniline in pharmaceutical wastewater, especially in the anaerobic digestion system, which leads to large sludge loss, decreased methane production and low energy recovery efficiency, limiting anaerobic digestion. Application of technology in pharmaceutical wastewater treatment.

Method used

Denitrification-enhanced anaerobic digestion (DEAD) process is used to convert ammonia nitrogen produced by anaerobic digestion into nitrate nitrogen and reflux to the anaerobic digestion stage. The denitrification oxidation provided by nitr nitrogen is used to promote the hydrolysis of difficult-to-degradable organic matter. Open ring with benzene ring, combined with anaerobic membrane biological reaction (AnMBR) technology, a denitrification strengthening system is built to improve the sludge proliferation rate and pollutant removal efficiency.

Benefits of technology

It has achieved efficient degradation of pollutants that are difficult to degrade in pharmaceutical wastewater, improved reaction rate and sludge concentration, reduced energy consumption and carbon emissions, improved effluent water quality and pollutant removal efficiency, and achieved synchronous carbon removal and nitrogen removal treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119038743A_ABST
    Figure CN119038743A_ABST
Patent Text Reader

Abstract

The invention discloses an anaerobic membrane biological treatment device and method for degradation-resistant pharmaceutical wastewater. The anaerobic membrane biological treatment device comprises a reactor, a membrane assembly, an adjusting tank, a flow dividing tank, a nitrification tank and a denitrification tank, the water inlet end of the membrane assembly is communicated with the reactor, the water outlet end of the membrane assembly is communicated with the flow dividing pool, the water outlet of the flow dividing pool is divided into two paths, one path is communicated with the nitrification pool, the other path is communicated with the denitrification pool, the water outlet of the nitrification pool is communicated with the adjusting pool, the nitrification pool is further connected with a high-ammonia-nitrogen wastewater inlet pipe, and the adjusting pool is further connected with a high-nitrate-nitrogen wastewater inlet pipe. A water outlet of the adjusting tank is communicated with the reactor. According to the invention, efficient anaerobic digestion treatment of pharmaceutical wastewater is realized by constructing a denitrification strengthening system, the membrane biological reaction technology is combined, the stock of sludge in the reactor is improved, the effluent quality is optimized, the degradation effect of the anaerobic digestion system on refractory pollutants in the pharmaceutical wastewater is further strengthened, the recycling of biomass energy substances is realized, and the treatment cost is reduced. The concepts of low-carbon emission reduction and waste resource utilization are practiced, and a good pollutant treatment effect is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical wastewater treatment, and in particular to an anaerobic membrane biological treatment device and method for difficult-to-degrade pharmaceutical wastewater. Background Art

[0002] Pharmaceutical wastewater is industrial wastewater produced during the pharmaceutical production process that contains a large amount of difficult-to-degrade pollutants. It has complex components and poses great harm to human health and environmental pollution. It usually has "three-hazard" properties. Therefore, it is very important to strengthen the efficient treatment of pharmaceutical wastewater. In recent years, with the requirements for the green development level of the API industry, the outstanding problems that restrict the development of the industry, such as pharmaceutical wastewater discharge, have been solved, and the development and application of clean production technologies and green and low-carbon wastewater treatment policies have been achieved.

[0003] However, for the hard-to-degrade organic pollutants in pharmaceutical wastewater, traditional biological treatment methods are usually difficult to treat high-concentration organic pollution, resulting in high energy consumption and large carbon emissions in the wastewater treatment process; and traditional chemical treatment processes based on advanced oxidation methods, although they can effectively degrade most hard-to-degrade organic matter, their huge drug consumption also results in high economic costs and carbon emissions. Therefore, the development of new technologies that integrate the characteristics of "green and low-carbon" and "biomass energy recovery" has become a new direction for the development of pharmaceutical wastewater treatment.

[0004] Pharmaceutical wastewater contains a large number of antibiotics, benzene, pigments, aromatic compounds and other difficult-to-degrade organic substances, as well as various acids, alkalis, tannins and anthraquinones. If the treatment is not up to standard, it will bring many negative impacts to the environment and restrict the sustainable development of the pharmaceutical industry. The pollution reduction and carbon reduction biological treatment technology based on anaerobic digestion has gradually become the mainstream choice for the treatment of high-concentration organic industrial wastewater due to its advantages such as low energy consumption and recyclable energy. Among them, aniline is the most representative substance of aromatic amines. It is a colorless oily liquid with an aromatic odor. It is widely used in printing and dyeing, plastics, pesticides and pharmaceutical industries. It is also a harmful substance that seriously pollutes the environment and endangers human health. Due to the characteristics of long-term residual, bioaccumulation, and carcinogenicity, aniline is listed as one of the priority pollutants to be controlled, and the molecule has thermal stability, making it a difficult-to-degrade pollutant. Due to the strong toxicity and poor biodegradability of aniline wastewater, existing biological treatment methods are difficult to effectively remove pollution, especially in anaerobic digestion systems. The hydrolysis stage is the rate-limiting stage for pollutant degradation. Therefore, the hydrolysis and ring-opening reaction efficiency of aniline is slow, which ultimately makes the hydrolysis and acclimation of anaerobic digestion sludge difficult, resulting in large sludge loss, reduced methane production, and low energy recovery efficiency, which seriously restricts the application of anaerobic digestion technology in the low-carbon treatment of pharmaceutical wastewater. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide an anaerobic membrane biological treatment device and method for difficult-to-degrade pharmaceutical wastewater, and propose a denitrification-enhanced anaerobic digestion (DEAD) process. On the basis of anaerobic digestion technology and anaerobic membrane biological reactor (AnMBR) technology, part of the ammonia nitrogen produced by anaerobic digestion is converted into nitrate nitrogen (nitric nitrogen), and the nitric nitrogen is returned to the anaerobic digestion stage. The denitrification oxidation effect provided by the nitric nitrogen is used to promote the strong hydrolysis of difficult-to-degrade organic matter in the pharmaceutical wastewater and the opening of the benzene ring, thereby avoiding the problem of limited hydrolysis rate of difficult-to-degrade organic matter in the pharmaceutical wastewater in the prior art, and forming a denitrification-enhanced anaerobic membrane biological treatment method for difficult-to-degrade pharmaceutical wastewater with simultaneous carbon removal and denitrification.

[0006] In order to solve the above technical problems, the present invention provides an anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater, comprising a reactor, a membrane module, a regulating tank, a diversion tank, a nitrification tank and a denitrification tank;

[0007] The water inlet end of the membrane assembly is connected to the reactor, and the water outlet end is connected to the diversion tank. A suction pump is installed on the pipeline between the membrane assembly and the diversion tank to pump the outlet water of the reactor into the membrane assembly for solid-liquid separation and then pump it out to the diversion tank;

[0008] The effluent from the diversion pool is divided into two paths, one path is connected to the nitrification pool, and the other path is connected to the denitrification pool;

[0009] The effluent from the nitrification tank is connected to a regulating tank, which is used to collect and mix pharmaceutical wastewater and nitrification tank return water;

[0010] The nitrification tank is also connected to a high-ammonia nitrogen wastewater inlet pipe, and the regulating tank is also connected to a high-nitric nitrogen wastewater inlet pipe, for replenishing nitric nitrogen for the reactor;

[0011] The water outlet of the regulating tank is connected to the reactor, and a gas outlet is arranged on the top of the reactor.

[0012] In the present invention, nitrogen-containing organic matter in pharmaceutical wastewater is degraded in a reactor to produce ammonia nitrogen, and the wastewater containing ammonia nitrogen enters a diversion tank and is diverted to a nitrification tank and a denitrification tank. In the denitrification tank, the ammonia nitrogen is subjected to a one-stage anaerobic ammonia oxidation (PN / A) denitrification treatment, and in the nitrification tank, the ammonia nitrogen is converted into nitric nitrogen and refluxed to the reactor after adjusting the carbon-nitrogen ratio in a regulating tank to construct a denitrification enhancement system. The stimulation of denitrification is utilized to promote the enhanced hydrolysis of difficult-to-degrade pollutants in pharmaceutical wastewater, induce a large number of proliferation of hydrolysis functional bacteria, and enhance the hydrolysis and benzene ring opening, which can not only effectively promote the anaerobic digestion degradation effect of difficult-to-degrade pollutants and improve the reaction rate, but also the AnMBR process can significantly enhance the proliferation rate of sludge in the system, maintain a high sludge concentration in the system, ensure sufficient hydrolysis reaction time, avoid sludge loss caused by cell decay and death, enhance the activity of anaerobic microorganisms in the system, improve the pollutant removal efficiency, enhance the methanation efficiency of organic matter, and the membrane interception effect can also efficiently remove SS (suspended solids) in effluent, improve effluent water quality, and reduce energy consumption and carbon emissions. In addition, this method improves the removal rate of organic matter, reduces the residual COD concentration in the anaerobic treatment effluent, and further provides a lower carbon-nitrogen ratio. Therefore, it can maintain the efficient operation of PN / A, improve the removal rate of total nitrogen in the wastewater, and achieve simultaneous carbon removal and denitrification treatment of pharmaceutical wastewater.

[0013] Taking aniline (chemical formula C6H7N), a common difficult-to-degrade pollutant in pharmaceutical wastewater, as an example, organic pollutants can be degraded into methane, carbon dioxide and ammonia nitrogen through a series of complex hydrolysis, oxygen ring opening, dehydrogenation, decarboxylation and methanogenesis by microorganisms under anaerobic conditions. The metabolic pathway is specifically divided into the following steps:

[0014] Aniline (dioxygenase) → catechol (dioxygenase) → 2-hydroxyhexadienesemialdehyde (dehydrogenase) → 4-oxalylcrotonate (decarboxylase) → 4-ene-2-ketovalerate → 4-hydroxy-2-ketovalerate (aldolase) → acetaldehyde + pyruvate …… ...

[0015] In the first step of reaction in formula (1), when aniline is degraded into catechol, ammonia nitrogen (NH4 + ), the acetaldehyde and pyruvic acid finally degraded are low molecular weight and easily degradable intermediates, which can be further utilized by acidogenic bacteria and methanogenic archaea in the anaerobic system to generate methane and carbon dioxide. The reaction formula is as follows:

[0016] CH3CHO+H2O→CH4+CO2……………………………………Formula (2)

[0017] CH3COCOOH+H2O→CH4+CO2………………………………Formula (3)

[0018] However, due to the difficulty in degrading aniline, the efficiency of a series of hydrolysis and ring-opening reactions of formula (1) is slow under anaerobic conditions, and the functional bacterial flora is difficult to domesticate. Since the reaction rate of formula (1) is limited, the reactions of formulas (2) and (3) lack the intermediate products acetaldehyde and pyruvate as methanogenic reaction substrates. Therefore, the overall organic matter removal rate is low, the methane yield is low, and the generated ammonia nitrogen concentration is also low, and further carbon-nitrogen synergistic removal cannot be achieved.

[0019] The present invention utilizes ammonia nitrogen (NH4 + ), a small amount of nitrate nitrogen (NO3 - ), the chemical reaction equation is as follows:

[0020] NH4 + +O2+OH - →NO3 - +H2O+H + ………………………………Formula (4)

[0021] The nitric nitrogen generated by the nitrification reaction is returned to the anaerobic digestion area for degrading aniline. Based on the principle that the reduction of nitric nitrogen in denitrification requires the consumption of organic carbon sources, a denitrification enhancement system (DEAD) is constructed. This small amount of nitric nitrogen plays a role in strengthening a series of hydrolysis and ring-opening reactions in formula (1). By consuming a small amount of aniline as an organic carbon source, a large number of bacteria that provide hydrolysis, oxygenation, dehydrogenase and other functions in formula (1) are guaranteed to proliferate, making the pharmaceutical wastewater anaerobic treatment system highly efficient. Among them, the equation for the denitrification reaction of the DEAD system constructed by the return of nitric nitrogen with a small amount of organic pollutants is:

[0022] C6H7N+NO3 - +H + →N2+NH4 + +CO2+HCO3 - ………………Formula (5)

[0023] A large amount of organic pollutants in pharmaceutical wastewater can achieve stable anaerobic digestion and methanogenesis under the enhanced action of DEAD system. The overall reaction equation is:

[0024] C6H7N+H2O→CH4+NH4 + +CO2+HCO3 - ……………………Formula (6)

[0025] The nitrate nitrogen that flows back to the anaerobic digestion area follows the reaction of formula (5) and is reduced to harmless nitrogen (N2) and mixed into the methane produced by anaerobic digestion. The methane content accounts for more than 70% of the total gas, while the nitrogen accounts for only about 20% (the additional nitrogen produced by denitrification increases the nitrogen content from 10% to about 20%), which can still ensure that the biogas has a high methane purity.

[0026] Furthermore, an air distribution module is arranged at the bottom of the membrane assembly, the aperture of the micropores on the air distribution module is 1±0.2 mm, the air distribution module is connected to an aeration pump, and the airflow generated by the aeration pump and the air distribution module directly flushes the membrane surface of the membrane assembly, which is more conducive to membrane pollution control.

[0027] Furthermore, a membrane pressure gauge is arranged on the pipeline between the membrane assembly and the filtration pump to monitor the transmembrane pressure (TMP), and a thermometer is arranged on the top of the reactor; a temperature control system is also included to control the temperature in the reactor at 35±2°C.

[0028] Furthermore, the carbon-nitrogen ratio of COD and nitrate nitrogen in the reactor influent is: 7<C / N<20. The nitrate nitrogen used preferentially is ammonia nitrogen produced by anaerobic digestion of nitrogen-containing organic pollutants in the pharmaceutical wastewater itself and then oxidized in the nitrification tank, so as to achieve self-sufficiency in nitrogen sources and reduce the cost of pharmaceutical investment. The relatively high C / N ratio will not affect the anaerobic digestion reaction in the reactor, and ensure that the methane purity in the biogas produced by the anaerobic system is high, otherwise the denitrification reaction will become dominant and replace the anaerobic digestion reaction without producing biological methane. The reflux of low-concentration nitrate nitrogen can take into account both the operating effect and the economic cost.

[0029] When there are fewer nitrogen-containing pollutants in pharmaceutical wastewater (such as amines, proteins, amino acids and other nitrogen-containing organic matter), the C / N ratio of the anaerobic digestion system is higher, resulting in a lower ammonia nitrogen concentration when the effluent from the reactor enters the diversion tank, which further leads to a lower nitric nitrogen concentration obtained by oxidation in the nitrification tank. Too low a nitric nitrogen concentration cannot guide sufficient denitrification reactions to compete for organic matter, and cannot enhance the degradation of difficult-to-degrade pollutants such as aniline through denitrification; when the carbon-nitrogen ratio C / N of COD and nitric nitrogen in the reactor inlet water is ≥20, nitric nitrogen is supplemented to the reactor through the high ammonia nitrogen wastewater inlet pipe and / or the high nitric nitrogen wastewater inlet pipe. Among them, the high ammonia nitrogen wastewater inlet pipe is connected to high ammonia nitrogen wastewater such as pesticide wastewater and landfill leachate, and the high nitric nitrogen wastewater inlet pipe is connected to high nitric nitrogen wastewater such as photovoltaic and electronic industry wastewater.

[0030] Furthermore, the carbon-nitrogen ratio of COD to total nitrogen in the wastewater of the diversion pool is less than 0.5, ensuring a good denitrification effect in the subsequent denitrification pool.

[0031] Furthermore, the hydraulic retention time of the reactor is 8-24h, and the organic load is ≤6.54kg / m 3 / d, the membrane flux of the membrane module is 1.86-3.72L / m 2 / h, the operating temperature should be maintained at 35±2℃, the COD removal efficiency can be stabilized to more than 90%, and the methane yield exceeds 0.75L CH4 / L wastewater. When the hydraulic retention time is greater than 8h, the operation is normal, and TMP does not surge significantly. When the hydraulic retention time is less than 6h, the shorter residence time is not conducive to the full hydrolysis and ring opening of difficult-to-degrade pollutants, the proliferation and enrichment of corresponding functional degradation bacteria, and the shorter residence time will accelerate the formation of membrane fouling, causing TMP to grow too fast, increasing the obstacles to membrane filtration, and ultimately reducing the service life of the membrane assembly and increasing the cost of membrane cleaning and maintenance.

[0032] Furthermore, the dissolved oxygen concentration in the nitrification tank is ≥2.0 mg / L, and an aeration system is installed at the bottom of the nitrification tank, using a continuous aeration mode to maintain the dissolved oxygen concentration at a high level, which can fully oxidize ammonia nitrogen into nitric nitrogen and assist in removing residual organic matter.

[0033] Furthermore, it also includes a control system, which is connected to the temperature control system, the membrane pressure gauge and the water pumps arranged in each pipeline of the processing device to achieve linkage control of the system processing.

[0034] Furthermore, the gas outlet of the reactor is connected to a water seal device and a gas flow meter in sequence.

[0035] Furthermore, a sludge discharge port is provided on the side of the reactor 2 cm away from the bottom, and sludge is discharged regularly according to the operating conditions of the reactor to avoid membrane pollution and membrane pore blockage caused by excessive internal sludge growth.

[0036] The second aspect of the present invention provides an anaerobic membrane biological treatment method for difficult-to-degrade pharmaceutical wastewater, using the device described in the first aspect, comprising the following steps:

[0037] S1. Pharmaceutical wastewater and nitrate-containing wastewater are mixed in a proportion in the regulating tank and then pumped into the reaction tank;

[0038] S2. The refractory pollutants in the pharmaceutical wastewater undergo a hydrolysis ring-opening reaction in the reaction tank under anaerobic conditions and are degraded into easily degradable intermediates and ammonia nitrogen. The easily degradable intermediates generate methane and carbon dioxide under the action of acid-producing bacteria and methanogenic archaea and are discharged from the gas outlet at the top of the reactor;

[0039] Among them, the nitric nitrogen introduced by the nitric nitrogen-containing wastewater consumes part of the difficult-to-degrade pollutants in the reactor to carry out denitrification reaction, thereby strengthening the hydrolysis and ring-opening reaction of the difficult-to-degrade pollutants;

[0040] S3, the effluent from the reactor enters the diversion tank after solid-liquid separation through the membrane assembly;

[0041] S4, the effluent of the diversion pool is divided into two paths, one path enters the denitrification pool to remove ammonia nitrogen through one-stage anaerobic ammonium oxidation, and the other path enters the nitrification pool for nitrification reaction to convert ammonia nitrogen into nitric nitrogen;

[0042] S5. The effluent from the nitrification tank flows back to the regulating tank.

[0043] Beneficial effects of the present invention:

[0044] The present invention realizes efficient anaerobic digestion treatment of pharmaceutical wastewater by constructing a denitrification enhancement system. Combined with membrane bioreactor technology, it increases the sludge stock in the reactor, optimizes the effluent quality, further enhances the degradation effect of the anaerobic digestion system on difficult-to-degrade pollutants in pharmaceutical wastewater, realizes the recycling of biomass energy materials, practices the concept of low-carbon emission reduction and waste resource utilization, and achieves good pollutant treatment effects.

[0045] The invention achieves enhanced anaerobic digestion to produce methane, improved treatment of difficult-to-degrade pollutants, improved effluent quality and recycling of by-products under low-input conditions, solving the problems of difficult treatment of difficult-to-degrade pharmaceutical wastewater and difficulty in resource recovery in current research, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 Schematic diagram of the structure of the anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater in Example 1 of the present invention;

[0047] Figure 2 Schematic diagram of the structure of the anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater in Example 2 of the present invention;

[0048] Figure 3 The long-term operation effect of Example 3 of the present invention on treating pharmaceutical wastewater: (a) inlet and outlet COD concentration and system COD removal rate; (b) effluent ammonia nitrogen generation concentration and methane yield; (c) inlet and outlet total nitrogen concentration and total nitrogen removal rate of the PN / A denitrification system (starting from the 40th day);

[0049] Figure 4 The long-term operation effect of the comparative example of the present invention in treating pharmaceutical wastewater: (a) COD concentration of inlet and outlet water and COD removal rate of the system; (b) ammonia nitrogen generation concentration of outlet water and methane yield; (c) total nitrogen concentration of inlet and outlet water and total nitrogen removal rate of PN / A denitrification system (starting from the 30th day)

[0050] Explanation of numbers in the figure: 1. Reactor; 2. Membrane assembly; 3. Equalization tank; 4. Diversion tank; 5. Nitrification tank; 6. Denitrification tank; 7. Filtration pump; 8. High ammonia nitrogen wastewater inlet pipe; 9. High nitrate nitrogen wastewater inlet pipe; 10. Aeration pump; 11. Membrane pressure gauge; 12. Thermometer; 13. Temperature control system; 14. Aeration system; 15. Control system; 16. Water pump; 17. Water seal device; 18. Gas flow meter. DETAILED DESCRIPTION

[0051] The present invention is further described below in conjunction with specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0052] Example 1

[0053] This embodiment provides an anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater, such as Figure 1 As shown, it includes a reactor 1, a membrane assembly 2, a regulating tank 3, a diverter tank 4, a nitrification tank 5 and a denitrification tank 6; the water inlet end of the membrane assembly 2 is connected to the reactor 1, and the water outlet end is connected to the diverter tank 4, and a suction pump 7 is installed on the pipeline between the membrane assembly 2 and the diverter tank 4, which is used to pump the effluent of the reactor 1 into the membrane assembly 2 for solid-liquid separation and then pump it out to the diverter tank 4; the effluent of the diverter tank 4 is divided into two paths, one path is connected to the nitrification tank 5, and the other path is connected to the denitrification tank 6; the effluent of the nitrification tank 5 is connected to the regulating tank 3, and the regulating tank 3 is used to collect and mix pharmaceutical wastewater and reflux water of the nitrification tank 5; the nitrification tank 5 is also connected to a high ammonia nitrogen wastewater inlet pipe 8, and the regulating tank 3 is also connected to a high nitric nitrogen wastewater inlet pipe 9, which is used to supplement nitric nitrogen for the reactor 1; the outlet of the regulating tank 3 is connected to the reactor 1, and an air outlet is arranged on the top of the reactor 1. In this embodiment, the reactor 1 and the membrane assembly 2 are designed as an integrated unit to form an anaerobic membrane bioreactor (AnMBR).

[0054] Preferably, an air distribution module is provided at the bottom of the membrane assembly 2, the pore size of the micropores on the air distribution module is 1±0.2 mm, the air distribution module is connected to the aeration pump 10, and the airflow generated by the aeration pump 10 and the air distribution module directly flushes the membrane surface of the membrane assembly 2, which is more conducive to membrane pollution control.

[0055] Preferably, a membrane pressure gauge 11 is provided on the pipeline between the membrane assembly 2 and the filtration pump 7, and the transmembrane pressure (TMP) is monitored by the membrane pressure gauge 11. A thermometer 12 is provided on the top of the reactor 1; a temperature control system 13 is also included for controlling the temperature in the reactor 1 at 35±2°C.

[0056] Preferably, the carbon-nitrogen ratio of COD and nitric nitrogen in the influent of the reactor 1 is: 7<C / N<20, and the nitric nitrogen used preferentially is ammonia nitrogen produced by anaerobic digestion of nitrogen-containing organic pollutants in the pharmaceutical wastewater itself, and then oxidized by nitrification tank 5, so as to achieve self-sufficiency in nitrogen source and reduce the cost of medicine. The relatively high C / N ratio will not affect the progress of the anaerobic digestion reaction in the reactor 1, and ensure that the methane purity in the biogas produced by the anaerobic system is high, otherwise the denitrification reaction will become dominant and replace the anaerobic digestion reaction without producing biological methane. The refluxing of low-concentration nitric nitrogen can take into account both the operation effect and the economic cost. When there are fewer nitrogen-containing pollutants in the pharmaceutical wastewater (such as nitrogen-containing organic matter such as amines, proteins, amino acids, etc.), the C / N of the anaerobic digestion system is higher, resulting in a lower ammonia nitrogen concentration when the effluent of the reactor 1 enters the diversion tank 4, which further leads to a lower nitric nitrogen concentration obtained by oxidation in the nitrification tank 5. Too low a nitrate nitrogen concentration cannot lead to sufficient denitrification reaction to compete for organic matter, and cannot enhance the degradation of difficult-to-degrade pollutants such as aniline through denitrification. When the carbon-nitrogen ratio C / N of COD and nitrate nitrogen in the influent of the reactor 1 is ≥20, nitrate nitrogen is supplemented to the reactor 1 through the high ammonia nitrogen wastewater inlet pipe 8 and / or the high nitrate nitrogen wastewater inlet pipe 9.

[0057] Preferably, the carbon-nitrogen ratio of COD to total nitrogen in the wastewater of the diversion tank 4 is less than 0.5, ensuring a good denitrification effect in the subsequent denitrification tank 6. The dissolved oxygen concentration in the nitrification tank 5 is ≥2.0 mg / L. An aeration system 14 is installed at the bottom of the nitrification tank 5, and a continuous aeration mode is adopted to maintain the dissolved oxygen concentration at a high level, which can fully oxidize ammonia nitrogen into nitric nitrogen and assist in removing residual organic matter.

[0058] Preferably, the hydraulic retention time of the reactor 1 is 8-24h, and the organic load is ≤6.54kg / m 3 / d, the membrane flux of the membrane assembly 2 is 1.86-3.72L / m 2 / h, the operating temperature should be maintained at 35±2℃, the COD removal efficiency can be stabilized to more than 90%, and the methane yield exceeds 0.75L CH4 / L wastewater. When the hydraulic retention time is greater than 8h, the operation is normal, and TMP does not surge significantly. When the hydraulic retention time is less than 6h, the shorter residence time is not conducive to the full hydrolysis and ring opening of difficult-to-degrade pollutants, the proliferation and enrichment of corresponding functional degradation bacteria, and the shorter residence time will accelerate the formation of membrane fouling, causing TMP to grow too fast, increasing the obstacles to membrane filtration, and ultimately reducing the service life of membrane assembly 2 and increasing the cost of membrane cleaning and maintenance.

[0059] Preferably, it also includes a control system 15, which is connected to the temperature control system 13, the membrane pressure gauge 11 and the water pump 16 arranged in each pipeline of the treatment device to realize the linkage control of the system treatment; the gas outlet of the reactor 1 is connected to the water seal device 17 and the gas flow meter 18 in sequence; a sludge discharge port is provided on the side of the reactor 1 2 cm away from the bottom, and sludge is discharged regularly according to the operating status of the reactor 1 to avoid membrane pollution and membrane pore blockage caused by excessive internal sludge proliferation.

[0060] Example 2

[0061] The difference between this embodiment and embodiment 1 is that the reactor 1 and the membrane assembly 2 are designed separately, that is, a separate AnMBR reactor 1 is used. Figure 2 As shown, at this time, the membrane assembly 2 is placed in an independent chamber outside the reactor 1, which is more conducive to regular maintenance and backwashing of the membrane assembly 2, achieving a longer operating life and a higher membrane flux. However, since it becomes two independent devices, the space occupancy is increased. The type of AnMBR reactor 1 can be selected according to actual needs.

[0062] Example 3

[0063] This embodiment provides an anaerobic membrane biological treatment method for difficult-to-degrade pharmaceutical wastewater. The actual pharmaceutical wastewater generated by a pharmaceutical company is anaerobic treated. The representative pollutants of the pharmaceutical wastewater include difficult-to-degrade organic matter such as aniline, and the COD concentration thereof is about 3000 mg / L. The device described in Example 1 is used, and the following steps are included:

[0064] (1) Water diversion: The effluent from the membrane module 2 is collected in the diversion pool 4 and diverted in a certain proportion by a drainage pump in the diversion pool 4. A small part of the effluent enters the nitrification pool 5, and the other part of the effluent enters the denitrification pool 6 for one-stage PN / A denitrification.

[0065] (2) Recovery and utilization of ammonia nitrogen: The diverted effluent is passed through the aerobic sludge of the nitrification tank 5 (where the dissolved oxygen is maintained at 2.0 mg / L) to completely degrade the residual COD in the diverted effluent and oxidize the ammonia nitrogen into nitric nitrogen.

[0066] (3) The high-concentration nitric nitrogen effluent produced by the nitrification tank 5 is returned to the regulating tank 3 through a drainage pump, and the carbon-nitrogen ratio of the influent COD and nitric nitrogen is adjusted to be greater than 7 and less than 20 by adjusting the influent ratio, and the mixed wastewater in the regulating tank 3 is re-entered into the reactor 1 through the drainage pump.

[0067] The hydraulic retention time of reactor 1 is 8-24h, and the organic load is not higher than 6.54kg / m 3 / d, the filtration membrane flux is 1.86-3.72L / m 2 / h, the sludge concentration in reactor 1 does not exceed 9.5g / L.

[0068] Depend on Figure 3 By comparison, it can be seen that after about half a month of acclimation, the COD removal rate of Example 3 was maintained at an average of about 93.6% from the 17th day. In addition, the removal rate of SS of suspended solids in the effluent can reach 100%, and the effluent does not contain SS at all. At the same time, the methane production also increased to 0.76L CH4 / L wastewater. Since the nitric nitrogen in the reflux liquid provides denitrification under anaerobic conditions, and guides the denitrifying bacteria to compete for carbon sources and consume part of the COD, methane accounts for (70-80%) in the biogas and always maintains the efficient operation of the anaerobic digestion system.

[0069] At the same time, due to the improvement of the COD removal rate of the anaerobic digestion system, the residual COD in the effluent was reduced, meeting the PN / A denitrification needs, and the average total nitrogen removal rate of the subsequent PN / A denitrification tank 6 (from the 53rd day to the 100th day) was also increased to about 83.6%, achieving efficient and simultaneous carbon removal and denitrification of difficult-to-degrade pharmaceutical wastewater.

[0070] Comparative Example 1

[0071] Using an upward anaerobic sludge blanket (UASB) as the anaerobic reactor 1, the actual pharmaceutical wastewater generated by a pharmaceutical company was anaerobically treated. The representative pollutants of the pharmaceutical wastewater included aniline and other difficult-to-degrade organic matter, and its COD concentration was about 3000 mg / L. Under the medium temperature condition of 35°C, the system could barely treat the pharmaceutical wastewater through long-term acclimatization of anaerobic sludge. However, Figure 4 As shown, the average removal rate of COD in pharmaceutical wastewater by UASB (from the 15th day to the 100th day) is only about 73.0%. Although the proportion of methane in biogas of UASB is high (about 85%), the total methane gas volume is not as good as the result of Example 3, and the methane production is only about 0.65L / L wastewater. There is still a small amount of SS residue in the effluent of UASB, and the SS concentration is about 20mg / L. From the 30th day onwards, the effluent of UASB is subjected to synchronous carbon and nitrogen removal, and PN / A is used as a denitrification process. However, due to the large amount of organic matter still remaining in the effluent of UASB, the average effluent COD concentration is 860mg / L. The higher COD residue directly limits the anaerobic ammonia oxidation reaction rate of the subsequent PN / A system, resulting in a decrease in the denitrification efficiency of the PN / A system, and the average total nitrogen removal rate is only about 72.7% during the stable period (from the 60th day to the 10th day), and the system stability is poor.

[0072] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. An anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater, characterized in that: It includes reactor, membrane module, regulating tank, diversion tank, nitrification tank and denitrification tank; The water inlet end of the membrane assembly is connected to the reactor, and the water outlet end is connected to the diversion tank. A suction pump is installed on the pipeline between the membrane assembly and the diversion tank to pump the outlet water of the reactor into the membrane assembly for solid-liquid separation and then pump it out to the diversion tank; The effluent from the diversion pool is divided into two paths, one path is connected to the nitrification pool, and the other path is connected to the denitrification pool; The effluent from the nitrification tank is connected to a regulating tank, which is used to collect and mix pharmaceutical wastewater and nitrification tank return water; The nitrification tank is also connected to a high-ammonia nitrogen wastewater inlet pipe, and the regulating tank is also connected to a high-nitric nitrogen wastewater inlet pipe, for replenishing nitric nitrogen for the reactor; The water outlet of the regulating tank is connected to the reactor, and a gas outlet is arranged on the top of the reactor.

2. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: An air distribution module is arranged at the bottom of the membrane assembly. The diameter of the micropores on the air distribution module is 1±0.2 mm. The air distribution module is connected to an aeration pump.

3. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: A membrane pressure gauge is arranged on the pipeline between the membrane assembly and the suction filtration pump, and a thermometer is arranged on the top of the reactor; a temperature control system is also included to control the temperature in the reactor at 35±2°C.

4. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: The carbon-nitrogen ratio of COD to nitric nitrogen in the reactor inlet water is: 7<C / N<20; When C / N≥20, nitric nitrogen is added to the reactor through the high ammonia nitrogen wastewater inlet pipe and / or the high nitric nitrogen wastewater inlet pipe.

5. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: The carbon-nitrogen ratio of COD to total nitrogen in the wastewater of the diversion pool is less than 0.

5.

6. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: The hydraulic retention time of the reactor is 8-24h, and the organic load is ≤6.54kg / m 3 / d, the membrane flux of the membrane module is 1.86-3.72L / m 2 / h.

7. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: The dissolved oxygen concentration in the nitrification tank is ≥2.0 mg / L.

8. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: It also includes a control system, which is connected to a temperature control system, a membrane pressure gauge, and a water pump arranged in each pipeline of the processing device.

9. The anaerobic membrane biological treatment device for difficult-to-degrade pharmaceutical wastewater according to claim 1, characterized in that: The gas outlet of the reactor is connected to a water seal device and a gas flow meter in sequence.

10. An anaerobic membrane biological treatment method for difficult-to-degrade pharmaceutical wastewater, using the device according to any one of claims 1 to 9, characterized in that: The steps include: S1. Pharmaceutical wastewater and nitrate-containing wastewater are mixed in a proportion in the regulating tank and then pumped into the reaction tank; S2. The refractory pollutants in the pharmaceutical wastewater undergo a hydrolysis ring-opening reaction in the reaction tank under anaerobic conditions and are degraded into easily degradable intermediates and ammonia nitrogen. The easily degradable intermediates generate methane and carbon dioxide under the action of acid-producing bacteria and methanogenic archaea and are discharged from the gas outlet at the top of the reactor; Among them, the nitric nitrogen introduced by the nitric nitrogen-containing wastewater consumes part of the difficult-to-degrade pollutants in the reactor to carry out denitrification reaction, thereby strengthening the hydrolysis and ring-opening reaction of the difficult-to-degrade pollutants; S3, the effluent from the reactor enters the diversion tank after solid-liquid separation through the membrane assembly; S4, the effluent of the diversion pool is divided into two paths, one path enters the denitrification pool to remove ammonia nitrogen through one-stage anaerobic ammonium oxidation, and the other path enters the nitrification pool for nitrification reaction to convert ammonia nitrogen into nitric nitrogen; S5. The effluent from the nitrification tank flows back to the regulating tank.

Citation Information

Patent Citations

  • Wastewater treatment system for synchronously decarbonizing and denitriding, and operation method thereof

    CN108059307A

  • Low-temperature sewage denitrification treatment system and method

    CN114890545A

  • Anaerobic membrane bioreactor coupled anaerobic ammonia oxidation wastewater biological denitrification productivity system

    CN117446970A

  • METHOD AND SYSTEM FOR TREATING WASTEWATER AND SLUDGES BY OPTIMIZING sCO2 FOR ANAEROBIC AUTOTROPHIC MICROBES

    US20130327709A1

Cited By

  • Method for treating metformin-containing wastewater by anaerobic microorganisms

    CN121269963A